Scientific publications

List of publications by Pharmatest

Published scientific papers including results from studies performed in Pharmatest

  1. Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model. International Journal of Molecular Sciences doi 10.3390/ijms22115570.
  2. Potential of Targeting Bone Metastases with Immunotherapies. Novel Approaches in Cancer Study doi: 10.31031/NACS.2019.03.000561.
  3. The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. International Journal of Molecular Sciences.
  4. Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone. Journal of Immunology Research doi: 10.1155/2019/4260987
  5. Characterization a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats.Translational Andrology and Urology doi: 10.21037/tau.2019.02.03.
  6. Novel and Conventional Preclinical Models to Investigate Bone Metastasis. Curr Mol Bio Rep 5:48–54.
  7. Chronic nonbacterial prostate inflammation in a rat model is associated with changes of gut microbiota that can be modified with a galactoglucomannan‐rich hemicellulose extract in diet. Wiley doi: 10.1111/bju.14553. 
  8. Antitumor Activity of Novel Bone-seeking, α-emitting 224Ra-solution in a Breast Cancer Skeletal Metastases Model. ANTICANCER RESEARCH 38(4): 1947-1955.
  9. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clin Cancer Res 23(15):4335-46.
  10. Galactoglucomannan-rich hemicellulose extract from Norway spruce (Picea abies) exerts beneficial effects on chronic prostatic inflammation and lower urinary tract symptoms in vivoInt J Biol Macromol 101 222-229.
  11. Intravesical treatment with cis-urocanic acid improves bladder function in rat model of acute bladder inflammation. Neurourol Urodyn 35(7):786-91.
  12. Importance of microenvironment in preclinical models of breast and prostate cancer. World J Pharmacol 4(1):47-57.
  13. Effects of afala and antiestrogen ICI 182,780 in the model of hormone-dependent prostate inflammation. Bull Exp Biol Med 156(6):807-9.
  14. Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis. J Natl Cancer Inst 105(12):908-916.
  15. Expression of metastasin S100A4 is essential for bone resorption and regulates osteoclast function.  Biochim Biophys Acta 1833(12):2653-63.
  16. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Cancer Res 10(5):597-604.
  17. Improved statistical modeling of tumor growth and treatment effect in preclinical animal studies with highly heterogeneous responses in vivo. Clin Cancer Res 18(16):4385-96.
  18. The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo. Osteoporos Int (2011) 22:2887–2893.
  19. ZP2307, a novel, cyclic PTH(1-17) analog that augments bone mass in ovariectomized rats. Bone 48:1319-1327.
  20. Models and screening assays for drug development in osteoporosis. Expert Opin Drug Discov 5:1163-1174.
  21. Effects of diet-induced obesity and voluntary wheel running on bone properties in young male C57BL/6J mice. Calcif Tissue Int 86:411-419.
  22. Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts. BMC Cancer.30;10:596.
  23. Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab 27:105-109.
  24. Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer. 12;9:362.
  25. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcif Tissue Int 82:108-115.
  26. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int 82:155-161.
  27. Effects of bioactive peptide, valyl-prolyl-proline (VPP), and lactobacillus helveticus fermented milk containing VPP on bone loss in ovariectomized rats. Ann Nutr Metab 51:65-74.

Selected other publications by Pharmatest staff

  1. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone 44:717-728.
  2. Fispemifene (Z-2-{2-[4-(4 Chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol), a novel selective estrogen receptor modulator, attenuates glandular inflammation in an animal model of chronic nonbacterial prostatitis. J Pharmacol Exp Ther. 327:58-67.
  3. Overexpression of human hydroxysteroid (17beta) dehydrogenase 2 induces disturbance in skeletal development in young male mice. J Bone Miner Res. 23(8):1217-26.
  4. Prostatic inflammation and obstructive voiding in the adult Noble rat: Impact of the testosterone to estradiol ratio in serum. Prostate, 68:1296-1306.
  5. Histopathological evidence for an association of inflammation with ductal PIN-like lesion but not with ductal adenocarcinoma in the prostate of the Noble rat. Prostate, 68:728-739.
  6. Role of cathepsin K in normal joints and in the development of arthritis. Curr Drug Targets 8:315-323. (Review)
  7. Tartrate-resistant acid phosphatase 5b as a marker of bone resorption (Review). Clin Lab 52:499-509.
  8. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 52:3713-3717
  9. Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur J Endocrinol. 152(2):301-14.
  10. Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun. 7;335(4):1095-101.
  11. Differential turnover of cortical and trabecular bone in transgenic mice overexpressing cathepsin K. Bone 36:854-865.
  12. Serum TRACP 5b Is a Useful Marker for Monitoring Alendronate Treatment: Comparison With Other Markers of Bone Turnover. J Bone Miner Res 20:1804-1812.
  13. Impaired bone resorption in cathepsin K deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36:159-172.
  14. Properties and expression of human tartrateresistant acid phosphatase isoform 5a by monocyte-derived cells. J Leukoc Biol. 77(2):209-18.
  15. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19:386-393.
  16. Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J Bone Miner Res.19(8):1320-8.
  17. Abnormal craniofacial development and expression patterns of extracellular matrix components in transgenic Del1 mice harboring a deletion mutation in the type II collagen gene. Orthod Craniofac Res 7:216-226.
  18. Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis. Ann Rheum Dis 63:649-655.
  19. Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res. 19(9):1432-40.
  20. A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J Bone Miner Res. 18(1):134-9.
  21. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 16:1444-1452.
  22. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 141(2):809-20.
  23. Tartrate-Resistant Acid Phosphatase 5b, a Novel Serum Marker of Bone Resorption. J Bone Miner Res 15:1337-1345.
  24. Alteration in the mechanical competence and structural properties in the femoral neck and vertebrae of ovariectomized rats. J Bone Miner Res.14(4):616-23.
  25. Effect of clodronate treatment on established bone loss in ovariectomized rats. Bone. 23(4):333-42.
  26. Comparison of three-point bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia. Bone 23:155-161.
  27. Clodronate prevents osteopenia and loss of trabecular connectivity in estrogen-deficient rats. J Bone Miner Res 13(2):287-96
  28. The effect of orally administered clodronate on bone mineral density and bone geometry in ovariectomized rats. J Pharmacol Exp Ther. 284(1):312-6
  29. Clodronate prevents bone loss in aged ovariectomized rats. Calcif Tissue Int. 61(2):151-7.
  30. Ovariectomy-induced bone loss can be affected by different intensities of treadmill running exercise in rats. Calcif Tissue Int. 60(5):441-8.
  31. Long-term effects of ovariectomy on the mechanical properties and chemical composition of rat bone. Bone 20(3):207-12
  32. Exercise can provide protection against bone loss and prevent the decrease in mechanical strength of femoral neck in ovariectomized rats. J Bone Miner Res. 9(10):1559-64.
  33. Effect of running exercise on the bone loss induced by orchidectomy in the rat. Calcif Tissue Int. 55(1):33-7.
  34. The mechanical strength of bone in different rat models of experimental osteoporosis. Bone 15:523-532.
  35. The effect of training on the recovery from immobilization-induced bone loss in rats. Acta Physiol Scand. 145(4):407-11.
  36. Effect of exercise on osteoporosis induced by ovariectomy in rats. Calcif Tissue Int. 49 Suppl:S80.